JM Financial Services
  • offerings
  • Markets
  • New badgeresources
  • Partner Us
Open Demat Account
  • Home
  • Company Information
  • Syngene International Ltd
S

Syngene International Ltd Share Price Healthcare
₹ (%)

  • NSE
  • BSE

What is Syngene International Ltd revenue and profit growth?

  • BSE Code 539268
  • NSE Symbol SYNGENE
  • ISIN Demat INE398R01022
  • Book Value (₹) 114.67
  • Face Value (₹) 10.00
  • Market Cap (₹ Cr.) 16,971.81
  • P/E (TTM) 44.29
  • EPS (TTM) 9.51
  • Div Yield (%) 0.30

Is Syngene International Ltd financially strong enough to invest in?

Today’s Low
Today’s High

52W Low
52W High

Open
Prev. Close
Volume

What corporate actions has Syngene International Ltd announced recently?

Syngene International Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 18, 2025

Syngene International Limited has informed the Exchange about Schedule of meet

Syngene International Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Apr 28, 2025

Syngene International Limited has informed the Exchange about Schedule of meet

Syngene International Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Apr 28, 2025

Syngene International Limited has informed the Exchange about Transcript

What is the history and background of Syngene International Ltd?

Syngene International Ltd is a listed subsidiary of Biocon. It is a contract research, development and manufacturing organisation (CRDMO) which provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies. The company was established in 1993 as  Syngene International Private Limited and initiated operations as a Custom Research Organisation (CRO) with services in chemistry and biology in 1994. In 2002, 99.9% of the company's equity shares were transferred to Biocon as Kiran Mazumdar Shaw, a promoter of Biocon, promoted it. As a result, the company became a subsidiary of Biocon. In 2007, the company signed the first long-term contract with Bristol-Myers Squibb to set up its first dedicated R&D centre. The company continued its growth trajectory and entered a collaboration with Endo Pharmaceuticals to develop novel biological therapeutic molecules against cancer in 2011. It crossed an annual turnover of over ₹5,000 million in 2013. The company’s erstwhile subsidiary, Clinigene International Limited (CIL), was amalgamated into the company in 2015. During the same year, the company was listed on BSE and NSE after an IPO. The company received the Golden Peacock Award for Risk Management in 2023.

Business Segments

  • Discovery Services:  Under this segment, the company is responsible for conducting early-stage research, from identifying biological targets relevant to disease in patient populations to delivering drug candidates for further development.
  • Development Services: The development services division takes drug candidates and provides various services, from pre-clinical to clinical trials, including drug substance, drug product development, and associated services.
  • Manufacturing Services: The company offers commercial-scale manufacturing of small molecules from its cGMP-compliant API manufacturing campus.
  • Dedicated R&D Centers: Under this segment, Syngene provides R&D services. The company’s  R&D Centers are multi-disciplinary teams based in dedicated facilities focusing on biopharmaceutical research for clients including BMS, Amgen and Baxter.
Subsidiary As of March 2023, the company has 3 subsidiaries listed below:
  • Syngene USA Inc. This wholly-owned subsidiary was incorporated in FY 2018 to support Syngene's firm foothold in the US market and allow easy access to its clients based in that region.
  • Syngene Scientific Solutions Limited (SSSL): This subsidiary was incorporated in 2022 and is engaged in contract research and clinical research services.
  • Syngene Manufacturing Solutions Limited (SMSL): This subsidiary was incorporated in  2022 to manufacture pharmaceutical, biopharmaceutical and biological products of any kind.

Key Personnel

Jonathan Hunt, Managing Director and Chief Executive Officer Jonathan holds is the current MD and CEO of the company. His responsibilities revolve around leading the company’s business and driving its investments in developing and strengthening its capabilities and capacities.  He holds a BA (Business Studies & Economics) degree from the University of Sheffield, UK, and has done his MBA from Durham University, United Kingdom. He held leadership positions at AstraZeneca for over a decade before joining Syngene.

Corporate Action

In 2019, the company issued bonus shares in the ratio of 1:1 on a record date of June 11, 2019.
Founded: 1993
Chairman: Kiran Mazumdar Shaw
Managing Director: Peter John Bains
Address: Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds, Bengaluru, Karnataka, 560099,
HO Tel: